MP305 INTRAVENOUS IMMUNOGLOBULIN G IN THE TREATMENT OF PATIENTS WITH IDIOPATHIC GLOMERULONEPHRITIS: CLINICAL EXPERIENCE LASTING 25 YEARS

Introduction and Aims: Glomerulonephritis(GN) accounts for 10%-20% of the total incident cases of end stage renal disease (ESRD), and is the third most common cause of ESRD after diabetes and hypertension in western countries. The pathogenesis of GN is prevalently immune mediated: humoral and cell-mediated immunity are involved, although the rationale for an etiological treatment is still lacking. In the last fifty years, empirical treatmentbased upon the use of corticosteroids (CS) and/or